Epigenetic silencing of DAPK1 by promoter methylation is a characteristic of sporadic CLL (Raval et al., 2007), indicating, therefore, that DAPKi was mainly targeting DAPK3 in these cells. The gene discussed is DAPK3; the disease is B-cell chronic lymphocytic leukemia.